Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Clinical Oncology

• Publication date

  2016-09-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2016.67.0182PMID 27091714
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance)

  2016cited by this paper
• Abstract S2-04: Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)

  2016cited by this paper
• Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

  2015cited by this paper
• Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer.

  2015cited by this paper
• TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

  2015cited by this paper
• Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

  2015cited by this paper
• Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement.

  2015cited by this paper
• Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

  2015cited by this paper
• Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012)

  2015cited by this paper
• Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

  2014cited by this paper
• Optimal systemic therapy for early breast cancer in women: a clinical practice guideline.

  2014cited by this paper
• Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.

  2014cited by this paper
• Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).

  2014cited by this paper
• Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

  2014cited by this paper
• Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

  2014cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013cited by this paper
• Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.

  2013cited by this paper
• Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.

  2013cited by this paper
• Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

  2012cited by this paper
• A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study

  2012cited by this paper
• Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

  2012cited by this paper
• Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

  2011cited by this paper
• Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.

  2011influential reference
• Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.

  2011cited by this paper
• Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.

  2010cited by this paper
• Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

  2010cited by this paper
• Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer.

  2009cited by this paper
• High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

  2009cited by this paper
• Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

  2009cited by this paper
• Adjuvant chemotherapy in older women with early-stage breast cancer.

  2009cited by this paper
• Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.

  2008cited by this paper
• Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

  2006cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

  2003cited by this paper

• Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025.

  2026cites this paper
• ‘Patients are left not knowing’: Trastuzumab (Herceptin) cardiac risk information and management in HER2-positive breast cancer—a qualitative study of patient experience

  2026cites this paper
• Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world study

  2025cites this paper
• Comparison of the Efficacy, Safety, and Quality of Life of Pegylated Liposomal Doxorubicin-Cyclophosphamide versus Epirubicin-Cyclophosphamide in Patients with Early-Stage HER2-Negative Breast Cancer: A Prospective, Randomized, Multicenter, Phase II Study

  2024cites this paper
• Drug Utilization Study of Anticancer Drugs in Breast Cancer Patients at a Tertiary Care Teaching Hospital

  2024cites this paper
• Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: A national population-based cohort study using routine data.

  2024cites this paper
• The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer—A Systematic Review and Meta-Analysis

  2024cites this paper
• Which Patients Need Chemotherapy? From Pathological Risk Factors to Gene Signatures and Evaluation of Endocrine Response

  2023cites this paper
• HER2 positive primary breast squamous cell carcinoma with good prognosis: a case report

  2023cites this paper
• Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers

  2023cites this paper
• Breast cancer and its therapeutic targets: A comprehensive review

  2023influential citation
• Implications of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer: clinical oncologist perspectives

  2023cites this paper
• Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer

  2023cites this paper
• Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study

  2023cites this paper
• Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.

  2022cites this paper
• Trends in heart disease mortality among breast cancer survivors in the US, 1975–2017

  2022cites this paper
• The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C

  2022influential citation
• Taxane‐induced neuropathy: How serious is this problem for patients with early breast cancer?

  2022cites this paper
• Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors

  2022cites this paper
• Unintended negative consequences of managing chemotherapy toxicity.

  2022cites this paper
• Adjuvant chemotherapy for pT1abN0M0 triple-negative breast cancer: a systematic review and meta-analysis of published studies.

  2021cites this paper
• Combination of Modern Radiotherapy and New Targeted Treatments for Breast Cancer Management

  2021cites this paper
• Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial.

  2021cites this paper
• Flexible care in breast cancer

  2021cites this paper
• Impact of taxane-based chemotherapy among older women with breast cancer on cognition and quality of life: a longitudinal pooled analysis

  2021cites this paper
• Health-Related Quality of Life Among Patients With HR+/HER2- Early Breast Cancer.

  2021cites this paper
• Disseminated cancer cells in breast cancer: mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities.

  2021cites this paper
• The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa

  2021cites this paper
• Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study.

  2021cites this paper
• Neoadjuvant chemotherapy with biosimilar trastuzumab in human epidermal growth factor receptor 2 overexpressed non-metastatic breast cancer: patterns of use and clinical outcomes in India

  2021cites this paper
• The value of first-line chemotherapy and targeted therapy in the treatment of breast cancer.

  2020cites this paper
• Cancer of the Breast

  2020cites this paper
• Randomised phase II trial evaluating the safety of peripherally inserted catheters versus implanted port catheters during adjuvant chemotherapy in patients with early breast cancer.

  2020cites this paper
• Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review

  2020cites this paper
• Initiation of adjuvant chemotherapy and trastuzumab for human epidermal growth receptor 2-positive early invasive breast cancer in a population-based cohort study of older women in England.

  2020cites this paper
• Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer.

  2020cites this paper
• Cancer genomics predicts disease relapse and therapeutic response to neoadjuvant chemotherapy of hormone sensitive breast cancers

  2020cites this paper
• Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer

  2020cites this paper
• Prognostic role of high cathepsin D expression in breast cancer: a systematic review and meta-analysis

  2020cites this paper
• Working together for the family: determination of HER oncogene co-amplifications in breast cancer

  2020cites this paper
• Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars

  2020cites this paper
• Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.

  2020cites this paper
• Clinical Profile of Carcinoma Breast Patients Treated with Trastuzumab: A Single Centre Study

  2020cites this paper
• Post-neoadjuvant treatment of breast cancer

  2020cites this paper
• Breast Cancer is not Just One Disease: A special focus of molecular heterogeneity of Triple Negative Breast Cancer

  2020cites this paper
• HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology.

  2019cites this paper
• Radiation treatment in early stage triple‐negative breast cancer in New Zealand: A national database study

  2019cites this paper
• Mimetic sHDL nanoparticles: A novel drug-delivery strategy to target triple-negative breast cancer.

  2019cites this paper
• Trastuzumab-Induced Cardiomyopathy.

  2019cites this paper
• Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives

  2019cites this paper
• Is trastuzumab as a single agent obsolete in early breast cancer? No.

  2019cites this paper
• HER2 overexpression and correlation with other significant clinicopathologic parameters in Ivorian breast cancer women

  2019cites this paper
• Efficacy and safety of taxane plus anthracycline with or without cyclophosphamide in Chinese node-positive breast cancer patients: an open-label, randomized controlled trial

  2019cites this paper
• Cancer prevention and screening: the next step in the era of precision medicine

  2019cites this paper
• Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.

  2019cites this paper
• Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia.

  2019cites this paper
• Necessity of In Situ Hybridization Test of Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Patients with Equivocal HER2 Immunohistochemistry Results

  2018cites this paper
• A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab

  2018cites this paper
• When and how to treat women with HER2-positive, small (pT1a-b), node-negative breast cancer?

  2018cites this paper
• Breast Cancer in Special Groups: Breast Cancer in Pregnancy

  2018cites this paper
• Biology, staging, and treatment of breast cancer during pregnancy: reassessing the evidences

  2018cites this paper
• Breast Cancer in Argentina: Feasibility for the Implementation of the New TNM Staging System 2018 in A Middle-Income Country

  2018cites this paper
• Optimizing Adjuvant and Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

  2018cites this paper
• Choice of chemotherapy regimen for early HER2-positive breast cancer in elderly patients.

  2018cites this paper
• Pharmacogenomics: Success and Challenges

  2018cites this paper
• Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.

  2018cites this paper
• THE BOTTOM LINE Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer : American Society of Clinical Oncology / College of American Pathologists Clinical Practice Guideline Focused Update Guideline Questions

  2018cites this paper
• Premature mortality due to breast cancer among Canadian women: an analysis of a 30-year period from 1980 through 2010

  2018cites this paper
• Efficacy and safety of the trastuzumab biosimilar candidate CT-P6.

  2018cites this paper
• Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies

  2018cites this paper
• The Global Need for a Trastuzumab Biosimilar for Patients With HER2‐Positive Breast Cancer

  2018cites this paper
• Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going

  2018cites this paper
• Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

  2018cites this paper
• Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review.

  2018cites this paper
• Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

  2018cites this paper
• Updates in the Evaluation and Management of Breast Cancer

  2018cites this paper
• Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients

  2018cites this paper
• Advances in the systemic treatment of triple-negative breast cancer.

  2018cites this paper
• Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update Summary.

  2018cites this paper
• Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology

  2018cites this paper
• Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer

  2018cites this paper
• Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials

  2018influential citation
• Predicting breast and axillary response after neoadjuvant treatment for breast cancer: The role of histology vs receptor status

  2018cites this paper
• Treatment patterns for adjuvant docetaxel-based chemotherapy in early-stage breast cancer in China: A pooled retrospective analysis of four observational studies.

  2018cites this paper
• Prostate Cancer Markers.

  2018cites this paper
• Thymidylate synthase predicts poor response to pemetrexed chemotherapy in patients with advanced breast cancer.

  2018cites this paper
• Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies.

  2018cites this paper
• Late Administration of Trastuzumab Emtansine Might Lead to Loss of Chance for Better Outcome in Patients with HER2-Positive Metastatic Breast Cancer

  2018cites this paper
• Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I–IIIB breast cancer receiving chemotherapy

  2018cites this paper
• Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer

  2018cites this paper
• Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.

  2018cites this paper
• Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis

  2018cites this paper
• Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

  2018cites this paper
• Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study

  2018cites this paper
• Optimizing treatment-sequencing strategies for the management of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: A Malaysian perspective

  2018cites this paper
• Real-life clinical pattern, management, and survival in Thai patients with early-stage or metastatic triple-negative breast cancer

  2018cites this paper
• A Rare Presentation of Primary Breast Carcinoma in the Vulva: A Case Report and Literature Review

  2017cites this paper
• Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer

  2017cites this paper
• Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.

  2017cites this paper
• Prognostic stratification of oestrogen receptor‐positive HER2‐negative lymph node‐negative class of breast cancer

  2017cites this paper